Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Fig. 3

Representative images of BRAF V600E immunohistochemical expression in two patients before treatment and in progression. a, c In the specimens before treatment we observed a homogeneous BRAF V600E grade 3 immunohistochemical expression. b, d In the samples when disease progressed we observed a less intense and more heterogeneous BRAF V600E staining. (Original magnification: ×20)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us